← Leaderboards
Hafiz Ahmed
University Of Md Biotechnology Institute
$5,709,933
Attributed
$5,729,933
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2009–24$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,729,933 · 8
By mechanism
R44$3,674,654 · 1
R43$1,760,008 · 5
R03$150,000 · 1
R41$145,271 · 1
Top collaborators
- Khairul Anam1 shared
Others in their field
Top investigators on “Galectin 3”
- Michael Demetriou · University Of California-Irvine$9,675,379
- Dean E. Brenner · University Of Michigan At Ann Arbor$9,229,997
- Pablo Argueso · Tufts Medical Center$8,138,825
- Vijay K Kuchroo · Brigham And Women'S Hospital$6,880,664
- Susan Heckbert · University Of Washington$5,892,912
- Quynh-Thu X Le · Stanford University$5,881,554
Research focus
Galectin 3Pharmaceutical PreparationsAffinityMediatingCellsBaseInflammationTechnologyBindingFrequenciesLigandsProductionSourceLicensingMouse ModelAgreementGenesExperimental StudyMalignant NeoplasmsAnimalsCell BankPharmacologic SubstanceGalactose Binding LectinImmune
Grant awards (12)
Targeting galectin-3 to overcome insulin resistance in type 2 diabetes$1,864,171
R44 · FY2024 · DK · contact PI
Targeting galectin-3 to overcome insulin resistance in type 2 diabetes$1,810,483
R44 · FY2023 · DK · contact PI
Targeting galectin-3 to intervene COVID-19$296,637
R43 · FY2023 · AI · contact PI
Targeting galectin-3 to intervene COVID-19$300,000
R43 · FY2022 · AI · contact PI
Targeting galectin-3 to overcome insulin resistance in type 2 diabetes$300,000
R43 · FY2020 · DK · contact PI
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy$300,000
R43 · FY2018 · CA · contact PI
Targeting galectin-3 for treatment of NASH mediated fibrosis$298,490
R43 · FY2018 · DK · contact PI
Targeting galectin-3 for prostate cancer therapy$224,881
R43 · FY2016 · CA · contact PI
Targeting galectin-3 for prostate cancer therapy$40,000
R43 · FY2016 · CA · contact PI
Early detection of prostate cancer in urine$145,271
R41 · FY2010 · CA · contact PI
Methylated Galectin-3 DNA as a Marker for Early Diagnosis of Prostate Cancer$75,000
R03 · FY2010 · CA · contact PI
Methylated Galectin-3 DNA as a Marker for Early Diagnosis of Prostate Cancer$75,000
R03 · FY2009 · CA · contact PI